DOACs in Atrial Fibrillation

For over 50 years, warfarin was the only oral anticoagulant available for stroke prevention in atrial fibrillation. While effective, it required regular INR monitoring, had numerous drug and food interactions, and carried significant bleeding risk. The development of direct oral anticoagulants (DOACs) targeting specific coagulation factors — thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) — promised a paradigm shift. RE-LY (2009) was the first landmark trial, demonstrating that dabigatran 150mg was superior to warfarin for stroke prevention with similar major bleeding.

Three more pivotal trials followed in rapid succession. ROCKET-AF (2011) demonstrated rivaroxaban was non-inferior to warfarin. ARISTOTLE (2011) showed apixaban was superior to warfarin for both efficacy (stroke prevention) and safety (major bleeding), establishing it as arguably the best-in-class agent. ENGAGE AF-TIMI 48 (2013) confirmed edoxaban's non-inferiority. Taken together, four large RCTs enrolling over 71,000 patients consistently demonstrated that DOACs were at least as effective as warfarin with more predictable pharmacokinetics and no monitoring requirement.

Guidelines rapidly incorporated DOACs. The ESC 2012 AF guidelines recommended DOACs as an alternative to warfarin. By the 2020 ESC AF guidelines, DOACs were preferred over warfarin for most patients (Class I, Level A). The 2024 ESC AF guidelines maintained this position, explicitly recommending DOACs over vitamin K antagonists in eligible patients. The AHA/ACC/HRS guidelines similarly endorsed DOACs as first-line therapy.

DOACs have largely replaced warfarin for stroke prevention in non-valvular atrial fibrillation worldwide. Current evidence debates focus on DOAC use in specific populations (mechanical heart valves remain a contraindication after REALIGN), optimal management of DOAC-associated bleeding, and the role of factor XIa inhibitors as next-generation anticoagulants with potentially even lower bleeding risk.